SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Cardiome -- CRME
CRME 2.330-2.1%May 16 5:00 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: dr.praveen who wrote (231)12/14/2007 1:53:24 PM
From: idos   of 285
 
Yes, negative opinion on tedisamil was no surprise due to its risk/benefit profile.
If the FDA approves IV vernakalant in January, do you believe it is likely to become the standard of care for acute pharmacologic conversion of AF? The proposed label that restricts use in pts w/ recent MI/ACS and recommends cautious use in CHF patients will narrow its commercial potential.

I have no position, just watching.

Regards,
Idit
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News